ArticleChemical science2026
A molecularly engineered rhenium platform triggers a self-enhancing RNS storm to disrupt tumor hypoxia and resultant immunosuppression.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) faces severe clinical limitations due to tumor hypoxia and an immunosuppressive microenvironment. To address these challenges, we rationally designed a rhenium-based system, RGCS@PEG nanoparticles. This platform incorporates a Cu-doped mesoporous silica core as an efficient carrier for the simultaneous loading of a rationally engineered Re-Bodipy photosensitizer (Re3) and the nitric oxide (NO) donor S-nitrosoglutathione (GSNO). The entire assembly is further coated with reactive oxygen species (ROS)-responsive thioketal-linked polyethylene glycol, enabling targeted payload release in the tumor microenvironment. The molecular design of Re3 facilitates highly efficient superoxide radical (˙O
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.